Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality
NCT ID: NCT06258629
Last Updated: 2024-02-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
40 participants
OBSERVATIONAL
2024-02-15
2025-02-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Pathogenesis and Prognostic Factors of Lymphoma
NCT06203652
Aberrant Expression of CD56 in Patients With Hematologic Malignancies.
NCT04546945
Clinical Application of Liquid Biopsy for Precise Diagnosis and Prognosis in Lymphoma
NCT04062877
Notch 1 Mutation in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patient
NCT07157579
Characteristics and Outcomes of Patients With Hematological Malignancies
NCT06402175
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group
Age and sex matched healthy control individuals
Flowcytometry on bone marrow aspiration
Flowcytometry on bone marrow aspiration
Case group
Available number of patients with newly diagnosed as hematological malignancy
Flowcytometry on bone marrow aspiration
Flowcytometry on bone marrow aspiration
Case group after 6 months
Available number of patients with newly diagnosed as hematological malignancy after 6 months of starting treatment.
Flowcytometry on bone marrow aspiration
Flowcytometry on bone marrow aspiration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Flowcytometry on bone marrow aspiration
Flowcytometry on bone marrow aspiration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1 Year
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Reem Yahia Hashim
resident of clinical pathology in sohag oncology center
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
sherine Ph aziz, resident
Role: CONTACT
References
Explore related publications, articles, or registry entries linked to this study.
Biondi A, Cazzaniga G. Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses. Hematology Am Soc Hematol Educ Program. 2013;2013:612-9. doi: 10.1182/asheducation-2013.1.612.
Carvajal LA, Neriah DB, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell K, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA, Verma A, Steidl U. Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia. Sci Transl Med. 2018 Apr 11;10(436):eaao3003. doi: 10.1126/scitranslmed.aao3003.
Chiaretti S, Vitale A, Cazzaniga G, Orlando SM, Silvestri D, Fazi P, Valsecchi MG, Elia L, Testi AM, Mancini F, Conter V, te Kronnie G, Ferrara F, Di Raimondo F, Tedeschi A, Fioritoni G, Fabbiano F, Meloni G, Specchia G, Pizzolo G, Mandelli F, Guarini A, Basso G, Biondi A, Foa R. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica. 2013 Nov;98(11):1702-10. doi: 10.3324/haematol.2012.080432. Epub 2013 May 28.
Coles SJ, Wang EC, Man S, Hills RK, Burnett AK, Tonks A, Darley RL. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia. 2011 May;25(5):792-9. doi: 10.1038/leu.2011.1. Epub 2011 Jan 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
soh-med-24-01-03MS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.